| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisals TA247: Tocilizumab for the treatment of rheumatoid arthritis (this has been partially replaced by TA375 - only covers DMARDs, not TNF inhibitors) and TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. |
|
Medicine details |
|
| Medicine name | tocilizumab (RoActemra®) |
| Formulation | concentrate for solution for infusion |
| Reference number | 311 |
| Indication | In combination with methotrexate (MTX), for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs or tumour necrosis factor antagonists. In these patients, tocilizumab can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate |
| Company | Roche Products Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 27/07/2012 |
| NICE guidance | |